Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Eur J Haematol ; 112(4): 554-565, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38083800

RESUMEN

OBJECTIVES: Flow cytometry with adenosine diphosphate (ADP) allows to characterize molecular changes of platelet function caused by this physiologically important activation, but the methodology has not been thoroughly investigated, standardized and characterized yet. We analyzed the influence of several major variables and chose optimal conditions for platelet function assessment. METHODS: For activation, 2.5 µM CaCl2 , 5 µM ADP and antibodies were added to diluted blood and incubated for 15 min. We analyzed kinetics of antibody binding and effects of their addition sequence, agonist concentration, blood dilution, exogenous calcium addition and platelet fixation. RESULTS: We tested our protocol on 11 healthy children, 22 healthy adult volunteers, 9 patients after a month on dual antiplatelet therapy after percutaneous coronary intervention (PCI), 7 adult patients and 14 children with immune thrombocytopenia (ITP). We found that our protocol is highly sensitive to ADP stimulation with low percentage of aggregates formation. The assay is also sensitive to platelet function inhibition in post-PCI patients. Finally, platelet preactivation with ITP plasma was stronger and caused increase in activation response to ADP stimulation compared to preactivation with low dose of ADP. CONCLUSIONS: Our assay is sensitive to antiplatelet therapy and platelet preactivation in ITP patients under physiological conditions with minimal percentage of aggregates formation.


Asunto(s)
Intervención Coronaria Percutánea , Púrpura Trombocitopénica Idiopática , Adulto , Niño , Humanos , Citometría de Flujo/métodos , Plaquetas/metabolismo , Púrpura Trombocitopénica Idiopática/terapia , Púrpura Trombocitopénica Idiopática/tratamiento farmacológico , Adenosina Difosfato/farmacología , Adenosina Difosfato/metabolismo , Adenosina Difosfato/uso terapéutico , Inhibidores de Agregación Plaquetaria/farmacología , Inhibidores de Agregación Plaquetaria/uso terapéutico , Agregación Plaquetaria , Activación Plaquetaria
2.
J Pediatr Hematol Oncol ; 46(3): e220-e222, 2024 04 01.
Artículo en Inglés | MEDLINE | ID: mdl-38447071

RESUMEN

Acquired thrombotic thrombocytopenic (aTTP) purpura is a life-threatening condition that can lead to devastating thromboembolic events. Recently, caplacizumab has been shown to rapidly restore platelet numbers and reduce the risk of severe end-organ damage when added to plasma exchanges (PEXs) and immunosuppression (IST). Here, we report the outcomes in 3 children with aTTP who were treated with caplacizumab in combination with PEXs and IST. In all 3 patients, platelet count increased to >15,000/mm 3 in 24 h and normalized on day 4, whereas normalization of ADAMTS13 activity >50% and elimination of the inhibitor was achieved after 18 to 89 days. Epistaxis was observed in 2 patients and was the only side effect related to caplacizumab. Caplacizumab is a promising agent for first-line treatment of children with aTTP.


Asunto(s)
Púrpura Trombocitopénica Trombótica , Anticuerpos de Dominio Único , Niño , Humanos , Púrpura Trombocitopénica Trombótica/tratamiento farmacológico , Intercambio Plasmático , Factor de von Willebrand , Terapia de Inmunosupresión , Proteína ADAMTS13
3.
Br J Haematol ; 202(3): 645-656, 2023 08.
Artículo en Inglés | MEDLINE | ID: mdl-37221654

RESUMEN

Wiskott-Aldrich syndrome (WAS) is an X-linked recessive disorder caused by WAS gene mutations resulting in haematopoietic/immune cell defects. Recent studies report accelerated death of WAS platelets and lymphocytes. Data on megakaryocyte (MK) maturation, viability and their possible role in thrombocytopenia development in WAS are limited. In this study we evaluate the MK viability and morphology in untreated, romiplostim-treated WAS patients compared with normal controls. The study included 32 WAS patients and 17 healthy donors. MKs were captured from bone marrow aspirates by surface-immobilized anti-GPIIb-IIIa antibody. Viability (by phosphatidylserine [PS] externalization), distribution by maturation stages and size of MK were determined by light microscopy. MK distribution by maturation stages in patients differed from controls. 40 ± 22% of WAS MKs versus 23 ± 11% of normal MKs were at maturation stage 3 (p = 0.02), whereas 24 ± 20% in WAS and 39 ± 14% in controls had megakaryoblast morphology (p = 0.05). Romiplostim treatment changed the MK maturation stages distribution close to normal. PS-positive (PS+) MK in WAS was significantly higher (21 ± 21%) than in healthy controls (2 ± 4%, p < 0.01). WAS patients with more damaging truncating mutations and higher disease score had higher PS+ MK fraction (Spearman r = 0.6, p < 0.003). We conclude that WAS MKs have increased cell death tendency and changes in maturation pattern. Both could contribute to thrombocytopenia in WAS patients.


Asunto(s)
Trombocitopenia , Síndrome de Wiskott-Aldrich , Humanos , Megacariocitos , Síndrome de Wiskott-Aldrich/genética , Plaquetas/metabolismo , Trombocitopenia/genética , Hematopoyesis
4.
Platelets ; 33(5): 727-734, 2022 Jul 04.
Artículo en Inglés | MEDLINE | ID: mdl-34749589

RESUMEN

Studies on platelet function in children older than neonatal period are few and their results are controversial. The pediatric platelets were alternatively reported to be more active or less active than adults' ones. We compared platelet function in the several age groups of children to adults and evaluated the age when platelet function reaches the adults' status. The study included 76 healthy children and 49 healthy adult volunteers. Types of platelet activation used included: collagen-related peptide (CRP) and PAR-1 activating peptide SFLLRN; SFLLRN, PAR-4 activating peptide AYPGKF and adenosine diphosphate (ADP); ADP. The parameters determined included forward (FSC) and side scatter (SSC), CD42b, CD61, CD62P, PAC-1, annexin V binding and mepacrine release levels. Resting pediatric platelets were similar to adults' platelets except for 1.2-fold decreased FSC and dense granules volume in youngest children, and 2.5-fold increased annexin V level in children aged 1-10 years. After CRP+SFLLRN stimulation, pediatric platelets had a 1.2-fold lower alpha- and 1.1-fold lower dense granule release than adults. For SFLLRN+AYPGKF+ADP stimulation, this was observed only for youngest children. The response to ADP stimulation was identical for pediatric platelets and adults. Pediatric platelets have lower granular release than adults' platelets, which persists until the age of 18.


Asunto(s)
Plaquetas , Activación Plaquetaria , Adenosina Difosfato/metabolismo , Adenosina Difosfato/farmacología , Adulto , Anexina A5/metabolismo , Plaquetas/metabolismo , Niño , Humanos , Péptidos
5.
Pediatr Blood Cancer ; 66(6): e27704, 2019 06.
Artículo en Inglés | MEDLINE | ID: mdl-30854783

RESUMEN

We retrospectively analyzed sequential therapy with romiplostim and eltrombopag in 23 children with immune thrombocytopenia: switching from romiplostim to eltrombopag (10 patients) or vice versa (13 patients). The median age of patients at enrollment in the study was 5.6 years (2-15 years). Switching from romiplostim to eltrombopag was effective in eight (80%) patients, whereas switching from eltrombopag to romiplostim was effective in eight (62%) patients. The response rate was similar in patients failing the first thrombopoietin receptor agonist and those who had previous response. To date, all responders continue to maintain platelets over 50 × 109 /L at 13-39 months after switching.


Asunto(s)
Benzoatos/administración & dosificación , Hidrazinas/administración & dosificación , Púrpura Trombocitopénica Idiopática/tratamiento farmacológico , Pirazoles/administración & dosificación , Receptores Fc/administración & dosificación , Receptores de Trombopoyetina/agonistas , Proteínas Recombinantes de Fusión/administración & dosificación , Centros de Atención Terciaria/normas , Trombopoyetina/administración & dosificación , Adolescente , Niño , Preescolar , Enfermedad Crónica , Femenino , Estudios de Seguimiento , Humanos , Masculino , Recuento de Plaquetas , Pronóstico , Púrpura Trombocitopénica Idiopática/sangre , Púrpura Trombocitopénica Idiopática/clasificación , Estudios Retrospectivos , Índice de Severidad de la Enfermedad
6.
Pediatr Transplant ; 21(5)2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28600850

RESUMEN

Recipient lymphocytes are crucial for direct and indirect pathways of allorecognition. We proposed that the administration of alemtuzumab several weeks pretransplantation could eradicate peripheral lymphatic cells and promote donor-specific acceptance. This was a single-center, retrospective review of 101 consecutive living donor kidney transplantations in pediatric patients (age 7 months-18 years), performed between September 2006 and April 2010. IS protocol included two 30 mg doses of alemtuzumab: The first was given 12-29 days prior to transplantation, and the second at the time of transplantation. Maintenance IS was based on combination of low-dose CNI and mycophenolate, with steroids tapered over the first 5 days post-transplantation. Patients were followed for 7.8±1.3 years, and protocol biopsies were taken 1 month, 1, 3, and 5 years post-transplant. The Kaplan-Meier 8-year patient and graft survival rates in the cyclosporine-treated patients were 82.0±7.3% and 71.6±7.3, and in the tacrolimus-treated patients were 97.2±5.4 and 83.8±6.0%. Biopsy-proven acute rejection developed in 35% of cyclosporine-treated patients and in 8% of tacrolimus-treated patients. Alemtuzumab pretreatment prior to LRD kidney transplantation, followed by maintenance immunosuppression with tacrolimus and MMF, is associated with reasonable long-term results in pediatric patients.


Asunto(s)
Alemtuzumab/administración & dosificación , Rechazo de Injerto/prevención & control , Inmunosupresores/administración & dosificación , Trasplante de Riñón , Donadores Vivos , Atención Perioperativa/métodos , Adolescente , Alemtuzumab/uso terapéutico , Niño , Preescolar , Esquema de Medicación , Femenino , Estudios de Seguimiento , Rechazo de Injerto/diagnóstico , Rechazo de Injerto/epidemiología , Supervivencia de Injerto , Humanos , Inmunosupresores/uso terapéutico , Quimioterapia de Inducción/métodos , Lactante , Trasplante de Riñón/métodos , Quimioterapia de Mantención/métodos , Masculino , Estudios Retrospectivos , Resultado del Tratamiento
7.
Pediatr Blood Cancer ; 62(9): 1597-600, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25946618

RESUMEN

BACKGROUND: Diamond Blackfan anemia (DBA) is a genetically and clinically heterogeneous ribosomopathy and inherited bone marrow failure syndrome characterized by anemia, reticulocytopenia, and decreased erythroid precursors in the bone marrow with an increased risk of malignancy and, in approximately 50%, physical abnormalities. METHODS: We retrospectively analyzed clinical data from 77 patients with DBA born in the Russian Federation from 1993 to 2014. In 74 families there was one clinically affected individual; in only three instances a multiplex family was identified. Genomic DNA from 57 DBA patients and their first-degree relatives was sequenced for mutations in RPS19, RPS10, RPS24, RPS26, RPS7, RPS17, RPL5, RPL11, RPL35a, and GATA1. RESULTS: Severe anemia presented before 8 months of age in all 77 patients; before 2 months in 61 (78.2%); before 4 months in 71 (92.2%). Corticosteroid therapy was initiated after 1 year of age in the majority of patients. Most responded initially to steroids, while 5 responses were transient. Mutations in RP genes were detected in 35 of 57 patients studied: 15 in RPS19, 6 in RPL5, 3 in RPS7, 3 each in RPS10, RPS26, and RPL11 and 1 each in RPS24 and RPL35a; 24 of these mutations have not been previously reported. One patient had a balanced chromosomal translocation involving RPS19. No mutations in GATA1 were found. CONCLUSION: In our cohort from an ethnically diverse population the distribution of mutations among RP genes was approximately the same as was reported by others, although within genotypes most of the mutations had not been previously reported.


Asunto(s)
Anemia de Diamond-Blackfan/genética , Factor de Transcripción GATA1/genética , Mutación , Proteínas Ribosómicas/genética , Anomalías Múltiples/genética , Adolescente , Anemia de Diamond-Blackfan/epidemiología , Niño , Preescolar , Anomalías Craneofaciales/genética , Análisis Mutacional de ADN , Femenino , Factor de Transcripción GATA1/deficiencia , Heterogeneidad Genética , Genotipo , Cardiopatías Congénitas/genética , Humanos , Lactante , Masculino , Fenotipo , Estudios Retrospectivos , Proteínas Ribosómicas/deficiencia , Federación de Rusia/epidemiología , Análisis de Secuencia de ADN , Adulto Joven
8.
J Pediatr Hematol Oncol ; 36(5): 395-401, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23823112

RESUMEN

Pediatric mature B-cell non-Hodgkin lymphomas (B-NHLs) are highly aggressive malignant tumors that are curable with chemotherapy (ChT). High-dose methotrexate (MTX) is considered indispensable for successful treatment, but this therapy frequently induces severe mucositis and infectious complications, especially in induction, which can cause treatment failure. A prospective multicenter trial of combined immunochemotherapy for advanced-stage B-NHL with rituximab and the modified NHL-BFM-90 protocol was conducted. The major differences from the original protocol were a decrease in the dose of MTX from 5000 to 1000 mg/m/24 h in the first 2 ChT blocks and the addition of rituximab at 375 mg/m to each of the first 4 blocks of ChT. Eighty-three newly diagnosed patients with a median age of 8.84 years with Burkitt lymphoma/leukemia and diffuse large B-cell lymphomas stage III to IV were included. Four patients died during induction ChT due to tumor lysis syndrome and infection. Two additional patients died subsequently due to tumor resistance. Complete remission was achieved in 77 (92.8%) patients; 2 patients relapsed at 1 and 3 months, and 2 developed secondary malignancies at 1 and 6.5 years, respectively, after the completion of therapy. The overall survival probability was 82%±8% with a median follow-up of 65.2 months. Combined therapy with rituximab and intensive ChT with a reduced MTX dose of 1 g/m in the 2 induction courses was feasible and produced high cure rates in patients with pediatric advanced-stage mature B-NHL.


Asunto(s)
Anticuerpos Monoclonales de Origen Murino/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Linfoma de Burkitt/tratamiento farmacológico , Quimioterapia de Inducción , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Adolescente , Linfoma de Burkitt/mortalidad , Linfoma de Burkitt/patología , Niño , Preescolar , Femenino , Estudios de Seguimiento , Humanos , Linfoma de Células B Grandes Difuso/mortalidad , Linfoma de Células B Grandes Difuso/patología , Masculino , Estadificación de Neoplasias , Pronóstico , Estudios Prospectivos , Inducción de Remisión , Rituximab , Tasa de Supervivencia
9.
Pediatr Transplant ; 17(2): 168-78, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-23442101

RESUMEN

Recipient parenchymal lymphatic cells are crucial for direct and indirect pathways of allorecognition. We proposed that alemtuzumab, being infused several weeks pretransplant could eradicate peripheral lymphatic cells and promote donor-specific tolerance. We present here a single center, retrospective review of 101 consecutive living-donor kidney transplantations to pediatric patients aged from seven month to 18 yr, performed between September 2006 and April 2010. Immunosupression protocol included two 30 mg doses of alemtuzumab: first given 12-29 d prior to transplantation and second at the time of transplantation. Maintenance immunosupression was based on combination of low dose and wide range CNI and mycophenolate. Patients were followed for 3.8 ± 1.4 yr and protocol biopsies were taken one month, one, and three yr post transplant. The Kaplan-Meier graft and patient survival was 96% and 97% for one yr, 89% and 93% for three yr. Biopsy proven acute rejection developed in 26% patients at one yr and in 35% at two yr, no rejections occurred beyond two yr. We conclude that alemtuzumab pretreatment prior to living related donor kidney transplantation allows to reach satisfactory middle-term results in pediatric patients with wide range and low CNI concentrations.


Asunto(s)
Anticuerpos Monoclonales Humanizados/uso terapéutico , Rechazo de Injerto/prevención & control , Inmunosupresores/uso terapéutico , Fallo Renal Crónico/cirugía , Trasplante de Riñón , Donadores Vivos , Acondicionamiento Pretrasplante/métodos , Adolescente , Alemtuzumab , Niño , Preescolar , Esquema de Medicación , Femenino , Estudios de Seguimiento , Supervivencia de Injerto , Humanos , Lactante , Estimación de Kaplan-Meier , Fallo Renal Crónico/mortalidad , Trasplante de Riñón/mortalidad , Masculino , Estudios Retrospectivos , Tasa de Supervivencia , Resultado del Tratamiento
10.
J Pediatr Hematol Oncol ; 35(8): e338-40, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-23128333

RESUMEN

A 26-year-old female with the classic major and minor components of autoimmune polyglandular syndrome type 1 was diagnosed as having pure red cell aplasia. Treatment with 1.5 g/d mycofenolate mofetil for 3 months failed to restore erythroid production. Treatment with cyclosporine A produced a good partial response but led to renal toxicity and was therefore substituted with cyclophosphamide, which had a good partial effect and lasted for 18 months. The relapse of anemia was not observed during the 6-month follow-up period after the cessation of treatment.


Asunto(s)
Ciclofosfamida/uso terapéutico , Inmunosupresores/uso terapéutico , Poliendocrinopatías Autoinmunes/complicaciones , Aplasia Pura de Células Rojas/tratamiento farmacológico , Adulto , Femenino , Humanos , Mutación , Poliendocrinopatías Autoinmunes/genética , Poliendocrinopatías Autoinmunes/fisiopatología , Aplasia Pura de Células Rojas/complicaciones , Aplasia Pura de Células Rojas/fisiopatología , Factores de Transcripción/genética , Proteína AIRE
11.
Front Immunol ; 8: 807, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28791007

RESUMEN

BACKGROUND: Nijmegen breakage syndrome (NBS) is a combined primary immunodeficiency with DNA repair defect, microcephaly, and other phenotypical features. It predominantly occurs in Slavic populations that have a high frequency of carriers with the causative NBN gene c.657_661del5 mutation. Due to the rarity of the disease in the rest of the world, studies of NBS patients are few. Here, we report a prospective study of a cohort of Russian NBS patients. METHODS: 35 Russian NBS patients of ages 1-19 years, referred to our Center between years 2012 and 2016, were prospectively studied. RESULTS: Despite the fact that in 80% of the patients microcephaly was diagnosed at birth or shortly thereafter, the average delay of NBS diagnosis was 6.5 years. Though 80% of the patients had laboratory signs of immunodeficiency, only 51% of the patients experienced significant infections. Autoimmune complications including interstitial lymphocytic lung disease and skin granulomas were noted in 34%, malignancies-in 57% of the patients. T-cell excision circle (TREC)/kappa-deleting recombination excision circle (KREC) levels were low in the majority of patients studied. Lower KREC levels correlated with autoimmune and oncological complications. Fifteen patients underwent hematopoietic stem cell transplantation (HSCT), 10 of them were alive and well, with good graft function. Three patients in the HSCT group and five non-transplanted patients died; tumor progression being the main cause of death. The probability of the overall survival since NBS diagnosis was 0.76 in the HSCT group and 0.3 in the non-transplanted group. CONCLUSION: Based on our findings of low TRECs in most NBS patients, independent of their age, TREC detection can be potentially useful for detection of NBS patients during neonatal screening. KREC concentration can be used as a prognostic marker of disease severity. HSCT is a viable treatment option in NBS and should be especially considered in patients with low KREC numbers early on, before development of life-threatening complications.

12.
Am J Med Genet A ; 120A(2): 174-9, 2003 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-12833396

RESUMEN

Nijmegen breakage syndrome (NBS, OMIM 251260) is a rare hereditary disease, characterized by immune deficiency, microcephaly, and an extremely high incidence of lymphoid tissue malignancies. The gene mutated in NBS, NBS1, was recently cloned from its location on chromosome 8q21. The encoded protein, nibrin (p95), together with hMre11 and hRad50, is involved in the double-strand DNA break repair system. We screened two Russian cohorts for the 657del5 NBS1 mutation and found no carriers in 548 controls and two carriers in 68 patients with lymphoid malignancies: one with acute lymphoblastic leukemia (ALL) and one with non-Hodgkin lymphoma (NHL). Several relatives of the second patient, who were carriers of the same mutation, had cancer (ALL, breast cancer, GI cancers). These preliminary data suggest that NBS1 mutation carriers can be predisposed to malignant disorders.


Asunto(s)
Rotura Cromosómica/genética , Trastornos Linfoproliferativos/genética , Trastornos Linfoproliferativos/patología , Mutación , Eliminación de Secuencia , Secuencia de Bases , Niño , Preescolar , Cromosomas Humanos Par 8 , Estudios de Cohortes , Predisposición Genética a la Enfermedad , Pruebas Genéticas , Heterocigoto , Humanos , Pérdida de Heterocigocidad , Linfoma no Hodgkin/genética , Linfoma no Hodgkin/patología , Masculino , Linaje , Proyectos Piloto , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/patología , Federación de Rusia , Síndrome
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA